Msd Drug Patent Portfolio
Msd owns 3 orange book drugs protected by 12 US patents Given below is the list of Msd's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9604948 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | 26 Nov, 2032 | Active |
| US10736896 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | 19 May, 2031 | Active |
| US11439642 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | 19 May, 2031 | Active |
| US8420656 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | 19 May, 2031 | Active |
| US8921377 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | 19 May, 2031 | Active |
| US9993476 | Substituted 5-flouro-1H-pyrazolopyridines and their use | 19 May, 2031 | Active |
| USRE46791 | Substituted dihydroquinazolines | 18 Jan, 2029 | Active |
| US8258132 | Pharmaceutical composition of a tachykinin receptor antagonist | 26 Sep, 2027 | Active |
| US6096742 | Polymorphic form of a tachykinin receptor antagonist | 01 Jul, 2018 | Expired |
| US5719147 | Morpholine and thiomorpholine tachykinin receptor antagonists | 17 Apr, 2015 | Expired |
| US5538982 | Medical use for tachykinin antagonists | 23 Jul, 2013 | Expired |
| US7214692 | Medical use for tachykinin antagonists | 18 Sep, 2012 | Expired |
Latest Legal Activities on Msd's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Msd.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Email Notification
Critical
| 01 May, 2024 | US10603384 |
| Patent eCofC Notification | 30 Apr, 2024 | US10603384 |
| Mail Patent eCofC Notification | 30 Apr, 2024 | US10603384 |
|
Email Notification
Critical
| 30 Apr, 2024 | US10603384 |
| Recordation of Patent eCertificate of Correction | 30 Apr, 2024 | US10603384 |
| Post Issue Communication - Certificate of Correction | 10 Apr, 2024 | US10603384 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Feb, 2024 | US8258132 |
|
Withdrawal of Application for PTE
Critical
| 07 Feb, 2024 | US8513255 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Jan, 2024 | US10736896 |
| Election in Response to Notice of Final Determination | 27 Dec, 2023 | US8513255 |
| Notice of Final Determination -Election Required | 14 Dec, 2023 | US8513255 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Sep, 2023 | US10603384 |
|
FDA Final Eligibility Letter
Critical
| 13 Jul, 2023 | US8513255 |
| Second letter to regulating agency to determine regulatory review period | 15 Jun, 2023 | US8420656 |
| Second letter to regulating agency to determine regulatory review period | 15 Jun, 2023 | US9604948 |
Msd's Drug Patent Litigations
Msd's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 26, 2005, against patent number US7214692. The petitioner , challenged the validity of this patent, with Russell Michael Hagan et al as the respondent. Click below to track the latest information on how companies are challenging Msd's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7214692 | July, 2005 |
Decision
(18 Jan, 2006)
| Russell Michael Hagan et al | |
Msd Drug Patents' Oppositions Filed in EPO
Msd drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 06, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP02796109A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP02796109A | Apr, 2009 | Hexal AG | Patent maintained as amended |
| EP02796109A | Apr, 2009 | Teva Pharmaceutical Industries Ltd. | Patent maintained as amended |
Msd's Family Patents
Msd Drug List
Given below is the complete list of Msd's drugs and the patents protecting them.
1. Emend
Emend is protected by 5 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8258132 | Pharmaceutical composition of a tachykinin receptor antagonist |
26 Sep, 2027
(1 year, 11 months from now)
| Active |
| US6096742 | Polymorphic form of a tachykinin receptor antagonist |
01 Jul, 2018
(7 years ago)
| Expired |
| US5719147 | Morpholine and thiomorpholine tachykinin receptor antagonists |
17 Apr, 2015
(10 years ago)
| Expired |
| US5538982 | Medical use for tachykinin antagonists |
23 Jul, 2013
(12 years ago)
| Expired |
| US7214692 | Medical use for tachykinin antagonists |
18 Sep, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Emend's drug page
2. Prevymis
Prevymis is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE46791 | Substituted dihydroquinazolines |
18 Jan, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prevymis's drug page
3. Verquvo
Verquvo is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9604948 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines |
26 Nov, 2032
(7 years from now)
| Active |
| US10736896 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
19 May, 2031
(5 years from now)
| Active |
| US11439642 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
19 May, 2031
(5 years from now)
| Active |
| US8420656 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
19 May, 2031
(5 years from now)
| Active |
| US8921377 | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
19 May, 2031
(5 years from now)
| Active |
| US9993476 | Substituted 5-flouro-1H-pyrazolopyridines and their use |
19 May, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Verquvo's drug page